Co-Diagnostics Vector Smart® Division Expands Footprint to 21 States

About this update from Co-diagnostics, Inc.

Expansion coincides with Co-Dx webinar for prospective mosquito abatement district customers in honor of National Mosquito Control Awareness Week SALT LAKE CITY, June 25, 2026 /PRNewswire/ --  Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its mosquito abatement district ("MAD") customer base for the Vector Smart® line of products and services have grown to include MADs in 21 states, with four new full laboratory installs added in June alone. The announcement coincides with Co-Dx hosting a webinar for prospective MAD customers in recognition of National Mosquito Control Awareness Week. "Our Vector Smart division continues to gain traction, and we believe the pace of new customer additions this month reflects both the strength of our technology and a growing urgency around vector-borne disease surveillance," said Dwight Egan, CEO of Co-Diagnostics. "Co-Diagnostics is a leader in the space to provide PCR tests to mosquito abatement districts for in-house PCR testing, decentralizing mosquito pool testing to allow for more informed operational decisions in communities where MADs operate." According to the World Health Organization , vector-borne diseases carried by mosquitos cause more than 700,000 deaths annually. In June 2026, Maricopa County, Arizona reported its first West Nile virus-related death of the season. Co-Dx Vector Smart products include multiplex PCR tests for diseases like West Nile, eastern and western equine encephalitis, St. Louis encephalitis, Zika, dengue and chikungunya, designed and optimized to help MADs improve their situational awareness of their communities and to make their abatement efforts more efficient and effective. Mr. Egan continued, "Co-Diagnostics believes that decentralizing PCR testing to the point of need enables faster, data-driven vector surveillance and better coordination between public health agencies. Because disease-carrying mosquitoes move across jurisdictional boundaries, timely collection and sharing of surveillance data can be critical to protecting communities. We are committed to remaining at the forefront of innovation for decentralized PCR, for vector control applications as well as infectious disease testing worldwide." About Co-Diagnostics, Inc.: Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View stock analysis, news, and events for Co-diagnostics, Inc.